KemPharm, Inc. (KMPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
KMPH POWR Grades
- Quality is the dimension where KMPH ranks best; there it ranks ahead of 83.41% of US stocks.
- KMPH's strongest trending metric is Growth; it's been moving up over the last 113 days.
- KMPH ranks lowest in Stability; there it ranks in the 1st percentile.
KMPH Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at -1.17 for Kempharm Inc; that's greater than it is for merely 5.37% of US stocks.
- With a year-over-year growth in debt of -96.3%, Kempharm Inc's debt growth rate surpasses just 1.55% of about US stocks.
- The volatility of Kempharm Inc's share price is greater than that of 98.8% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Kempharm Inc are AQST, ACRX, OMER, PRTK, and RDUS.
- KMPH's SEC filings can be seen here. And to visit Kempharm Inc's official web site, go to kempharm.com.
KMPH Stock Price Chart Interactive Chart >
KMPH Price/Volume Stats
|Current price||$13.58||52-week high||$22.08|
|Prev. close||$15.47||52-week low||$3.84|
|Day high||$15.21||Avg. volume||2,759,146|
|50-day MA||$10.33||Dividend yield||N/A|
|200-day MA||$10.50||Market Cap||387.13M|
KemPharm, Inc. (KMPH) Company Bio
KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.
KMPH Latest News Stream
|Loading, please wait...|
KMPH Latest Social Stream
View Full KMPH Social Stream
Latest KMPH News From Around the Web
Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.
CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders to be held on June 17, 2021. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022. The
CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in accordance with the 2021 Russell indexes annual reconstitution. KemPharm’s anticipated inclusion in the Russell indexes will be effective after the U.S. market opens on Monday, June 28, 2021. "The expected
KemPharm (KMPH) announces that six U.S. patents governing serdexmethylphenidate ((SDX)), the company's prodrug of d-methylphenidate (d-MPH), and Azstarys, are now listed in the “Orange Book.” Among the listed patents, U.S. Patent No. 9,079,928, due to expire on July 27, 2032, is a composition of matter patent.The other five U.S. patents are...
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status
SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™ CELEBRATION, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that six U.S. patents governing serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), and AZSTARYS™, are now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.” In addition, the Orange Book listing confirms the status of SDX, which is the primary API in AZSTARYS, as a new chemical entity (NCE), which provides at least...
Corporate and Regulatory Highlights AZSTARYSTM NDA approved by the FDA on March 2, 2021Announced amendment to Licensing Agreement with Gurnet Point Capital affiliate following FDA approval of AZSTARYSReceived FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use DisorderSerdexmethylphenidate (SDX) classified as a Schedule IV Controlled Substance by the DEA Financial Highlights Completed financial restructuring, which resulted in re-listing on The Nasdaq Capital Market, receipt of approximate gross proceeds of $94 million and no debtReported Q1 2021 revenue of $12.1 millionQ1 2021 net loss of ($0.54) per basic share and diluted share compared to a net loss of ($1.92) per basic share and diluted share for Q1 2020Total cash, cash equivalents and restricted cas...
KMPH Price Returns